Thomas Schinecker, Roche CEO (ddp images/Sipa USA/Sipa via AP Images)

April 24, 2024 07:12 AM EDT

Roche doubles down on high-impact projects after slashing 20% of its pipeline

Ayisha Sharma

News Reporter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Hinge Health is going public on Thursday at a $3B valuation

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

FDA asks Covid vaccine makers to add more myocarditis data to labels

Updated: Eikon Therapeutics cuts staff for the second time in less than two years

Altos Labs buys anti-aging startup Dorian Therapeutics

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?